(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 December 2016 (22.12.2016)   WIPO | PCT

(10) International Publication Number
WO 2016/203052 A1

(54) Title: IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN ANTIBODY AGAINST RSV PREFUSION F PROTEIN

Figure 5

C


```
                                    20                    CDR1              40
                                     |                     |                 |
        DS-Cav1-4   QVQLQESGGGLVQPGGSLRLSCAAS GFTLDYYYIG WFRQA 40
        DS-Cav1-L66 QVQLQESGGGLVQPGGSLRLSCAAS GFTLDYYYIG WFRQA 40
                                          CDR2  60                       80
                                                |                         |
        DS-Cav1-4   PGKEREAVS CISGSSGSTYYPDSVKG RFTISRDNAKNTVY 80
        DS-Cav1-L66 PGKEREGVS CISSSHGSTYYADSVKG RFTISRDNAKNTVY 80
                                               100     CDR3          120
                                                 |       |             |
        DS-Cav1-4   LQMNSLKPEDTAVYYCAT IRSSSWGGCVHYGMDY WGKGTQ 120
        DS-Cav1-L66 LQMNSLKPEDTAVYYCAT VAVAHFRGCGVDGMDY WGKGTQ 120
                              6xHIS
        DS-Cav1-4   VTVSS HHHHHH 131
        DS-Cav1-L66 VTVSS HHHHHH 131
```

(57) **Abstract**: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.

IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN ANTIBODY
AGAINST RSV PREFUSION F PROTEIN

Field of the invention

The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed
against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion
form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for
prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these
ISVDs.

Background

Respiratory syncytial virus is the most important cause of acute airway infections in infants and young
children. By the age of two nearly all children will have undergone at least one respiratory syncytial virus
infection. Although usually causing only mild disease, in a fraction of patients (1-2%) RSV infection leads
to serious bronchiolitis where hospitalization is required. It has been estimated that each year 160.000
children die due to RSV infection. No effective prophylactic vaccine and no RSV-specific therapeutic small
molecule are clinically developed. The only way in which high-risk infants can be partially protected from
a severe disease caused by an anticipated RSV infection is by monthly injections with a humanized mouse
monoclonal antibody directed against the pre- and postfusion conformation of the F protein of RSV
(palivizumab). Nevertheless, treatment with this antibody is expensive and only used in a prophylactic
setting. Several other RSV F protein binding agents are being developed, including prefusion specific
monoclonal antibodies (Gilmans et al., 2015; McLellan et al., 2013), and a RSV F protein binding ISVD.
However, the described ISVD has weak neutralization activity against RSV serotype B and/or multivalent
formatting is needed to render the ISVD potent (WO2009147248; WO2010139808; WO2011064382;
Schepens et al., 2011; Hultberg et al., 2011).

Recently, it was shown that conventional antibodies that specifically bind to the prefusion conformation
of the RSV F protein are much more potent in vitro RSV neutralizers than antibodies that bind both the
post- and the prefusion conformation of F (WO2008147196, US2012070446, McLellan et al., 2013).
However, conventional antibodies can be cumbersome to produce and their stability may be limited.
Furthermore, due to their relatively large size conventional antibodies can be hindered in their cognate
epitope recognition in complex samples or when other antibodies and ligands are occupying sites in the
vicinity of their epitopes.

Accordingly, and as there is no widely accepted treatment available, there is an unmet need for a potent
anti-RSV drug which can be used for effective treatment and/or prevention of RSV infections.

Summary

It is surprisingly shown herein that monovalent ISVDs can have strong neutralization activity against both RSV serotypes (A and B). This is unexpected, as literature suggests that multivalent constructs are needed for potent inhibition of both serotypes of RSV. Accordingly, it is an object of the invention to provide ISVDs directed against epitopes of the RSV F protein that are unique to the prefusion conformation and thereby provide highly potent ISVDs for the treatment and/or prevention of RSV infections.

It is an aspect of the present invention to provide an ISVD that binds specifically to the prefusion form of the F protein of RSV, characterized in that said ISVD shows in monovalent format a similar neutralization activity of RSV serotypes A and B.

In one embodiment, the invention envisages an ISVD that comprises a CDR1 sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, a CDR2 sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4 and a CDR3 sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 6 and wherein CDR1, CDR2 and/or CDR3 have a 1-, 2- or 3-amino acid difference with any of said foregoing respective SEQ ID NOs.

According to another aspect, the invention also relates to a RSV binding construct that comprises at least one ISVD as described above.

According to another aspect, the invention envisages a nucleic acid that encodes at least one ISVD as described above.

According to yet another aspect, the present invention relates to a host cell that is transformed or transfected with the nucleic acid as described above. Also envisaged is the use of the above described host cell for the production of the ISVD as described above.

Also envisaged is the ISVD as described above or the RSV binding construct as described above, for use as a medicament, in particular for use in therapeutic treatment or prevention of a RSV infection.

According to another aspect, the invention envisages a pharmaceutical composition that comprises at least one ISVD as described above. Further envisaged is the use of said pharmaceutical composition as a medicament, in particular in therapeutic treatment or prevention of a RSV infection.

Objects of the present invention will be clear from the description that follows.

Brief description of the Figures

Figure 1: Neutralizing activity in plasma from llama immunized with DS-Cav1. Neutralizing activity against RSV A2 (A) and RSV B49 (B) was tested in the plasma obtained after different immunizations with

5   DS-Cav1. Monolayers of Vero cells seeded in 96-well plates were infected with RSV A2 or RSV B49 in the presence of llama plasma, threefold diluted as indicated in the X-axis and starting with eightfold dilution. The number of plaques in each well was counted and is depicted in the Y-axis. Pre DS-Cav 1 corresponds to the pre-immune serum of the immunized llama.

Figure 2: Selection of VHHs that bind to purified recombinant RSV fusion protein (F). ELISA plates were

10   coated with DS-Cav1 (grey bars, prefusion F), postfusion F (black bars) or BSA. The plates were incubated with bacterial periplasmic space extracts prepared from pHEN4-VHH transformed TG1 E. coli cells that had been obtained after one round of panning against DS-Cav1 with the VHH-displaying phage library generated from the PBMCs of the DS-Cav1 immunized llama. In the graph, the binding to the F protein is depicted as the log2 ratio of OD450 values over binding to BSA.

15   **Figure 3: Detection of RSV neutralizing activity in Pichia pastoris supernatants.** pKai61-VHH *P. pastoris* transformants were pre-cultured in 2 ml YPNG medium in a 24-well format for 24 hours. Subsequently, the cells were placed in YPNM medium for 48 hours to induce VHH expression. 1/60, 1/600 and 1/6000 dilutions of the cleared culture supernatant were tested for neutralizing activity by mixing with RSV A2 (30 PFU/well), which was used to inoculate a monolayer of Vero cells. Boxes indicate *P. pastoris* clones

20   with neutralizing activity. (**A**) *P. pastoris* clones obtained after transformation with a select set of unique pKai61-VHH plasmids, referred to by the numbers. (**B**) *P. pastoris* clones obtained after transformation with pKai61 in which a library of candidate F-specific VHHs was cloned. L3, L13, etc. refer to individual *P. pastoris* transformants. Boxed wells indicate samples with RSV-neutralizing activity.

Figure 4: Purification of VHHs produced in Pichia pastoris. The culture medium of P. pastoris cells that

25   had been transformed with pKai-VHH-DS-Cav1-4, pKai-VHH-DS-Cav1-L66, pKai-VHH-F2 or pKai-VHH-F58 was harvested after induction with methanol for 96 h. Resolubilized ammonium sulphate precipitate of the cell-free medium was loaded onto a HisTrap column and after washing the column was eluted with an increasing concentration gradient of imidazole (left). The peak fraction that eluted from the HisTrap column was subsequently loaded on a Superdex 75 gelfiltration column (right). The chromatographs are

30   shown for VHH-DS-Cav1-4 (A), VHH-DS-Cav1-L66 (B), VHH-F2 (C) and VHH-F58 (D).

Figure 5: Nucleotide sequences of VHH-DS-Cav1-4 (A) and VHH-DS-Cav1-L66 (B) and predicted amino acid sequences of recombinant VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 produced in P. pastoris (C). The Complementarity Determining Regions (CDRs) and His tag (6xHIS) are indicated by labeled boxes.

Figure 6: VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 have potent RSV neutralizing activity. Vero cells were
5   infected with RSV A2 (A) or RSV B49 (B) in the presence of purified VHH (VHH-DS-Cav1-4, VHH-DS-Cav1-L66 or negative control NB 1.14), monoclonal antibody D25 or monoclonal antibody AM22. VHHs and monoclonal antibodies were applied in a threefold dilution series starting with a concentration of 3,000 ng/ml. The 50% inhibitory concentration (IC50) was calculated based on the plaque reduction shown in A and B and is depicted in (C). IC_{50} values for F-VHH-4 (DS-Cav1-4) and F-VHH–L66 (DS-Cav1-L66)
10   compared to Ctrl-VHH and mAbs against HMPV-A1-GFP, hMPV-B1-GFP and RSV A2-GFP (D). Pre-determined amounts of GFP-expressing hMPV recombinant viruses (NL/1/00 A1 sublineage or NL/1/99 B1 sublineage, a kind gift of Bernadette van den Hoogen and Ron Fouchier, Rotterdam, the Netherlands) or GFP-hRSV (A2 strain, a kind gift of Mark Peeples, Columbus, Ohio, USA) (MOI 0.3 ffu/cell) were mixed with serial dilutions of VHHs or mAbs and added to cultures of either Vero-118 (hMPV) or HEp-2 cells,
15   growing in 96-well plates. Thirty-six hours later, the medium was removed, PBS was added and the GFP fluorescence in each well was measured with a Tecan microplate reader M200. Fluorescence values were plotted as percent of a virus control without antibody and used to calculate the corresponding IC_{50} values.

Figure 7: VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 bind to DS-Cav1 but not to postfusion F. (A) ELISA plates
20   were coated with DS-Cav1 (upper panel) or postfusion F (lower panel). The plates were incubated with a 1/3 dilution series of purified VHH-DS-Cav1-4, VHH-DS-Cav1-L66 and VHH-F58 starting from 30,000 ng/ml. The OD450 values are depicted. (B) Surface plasmon resonance (SPR) sensorgrams of the binding of VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 to immobilized prefusion or postfusion F protein. In the top panel, depicting SPR sensorgrams for prefusion F, a buffer-only sample was injected over the DS-Cav1
25   (prefusion F) and reference flow cells, followed by 2-fold serial dilutions of VHH-DS-Cav1-4 or VHH-DS-Cav1-L66 ranging from 5 nM to 39.1 pM, with a duplication of the 1.25 nM concentration. The data were double-reference subtracted and fit to a 1:1 binding model (red lines). The lower panels depict SPR sensorgrams for binding of VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 to immobilized postfusion F. A buffer-only sample was injected over the postfusion F and reference flow cells, followed by 1 µM and 500 nM
30   concentrations of DS-Cav1-4 or DS-Cav1-L66. The data were double-reference subtracted, but were not fit to a binding model, as no binding to postfusion F was detected.

Figure 8: VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 bind to F on the surface of mammalian cells. HEK-293T cells were transfected with a RSV A2 F protein expression vector (pCAGGS-Fsyn) in combination with a

GFP-NLS expression vector (peGFP-NLS) or transfected with only the GFP-NLS expression vector. The graph shows the median fluorescence intensity (FI) of the indicated VHHs and an RSV F specific mouse monoclonal antibody (MAB858-1, Millipore) to GFP positive cells expressing either the RSV F protein (top graph) or not (bottom graph).

Figure 9: Antibody cross-competition on DS-Cav1-binding analyzed by using biolayer interferometry. DS-Cav1 was immobilized on AR2G biosensors through amine coupling reaction in acetate buffer. The reaction was quenched by 1M ethanolamine and DS-Cav1-immobilized biosensors were then equilibrated with assay buffer (PBS with 1% BSA). The biosensors were dipped in competitor antibodies/VHHs followed by analyte antibodies/VHHs with a short baseline step in between two antibody/VHH steps. Percent inhibitions were defined by comparing binding maxima of the analyte antibody/VHH in the absence and presence of each competitor. NB: no binding.

Figure 10: Prophylactic administration of DS-Cav1-4 and DS-Cav1-L66 reduces RSV replication in vivo. 30 µg of DS-Cav1-4, DS-Cav1-L66 or F2, and 30 µg of palivizumab was administered intranasally to BALB/c mice four h prior to challenge with RSV A2. Twenty four h after infection all mice received 30 µg of F2 intranasally. Mice were sacrificed on day five after challenge and the virus load in the lungs was determined by plaque assay (A) and by qRT-PCR (B). Each data point represents one mouse and the horizontal lines depict the median. #: Mouse with virus titer in lung homogenate below detection limit. Graph (B) represents the relative expression of RSV RNA, normalized to mRPL13A mRNA levels present in the samples of each mouse in the indicated groups.

Figure 11: VHH-DS-Cav1-4 and VHH-DS-Cav1-L66 bind the same epitope on RSV F, with high structural conservation. (A) Buried Surface Area and Residues on prefusion-stabilized RSV F (SEQ ID NO: 16) that are contacted by VHH-DS-Cav1-4 (shown in bold). (B) Buried Surface Area and Residues on prefusion-stabilized RSV F (SEQ ID NO: 16) that are contacted by VHH-DS-Cav1-L66 (shown in bold). (C) The amino acid residues of the prefusion-stabilized RSV F protein full open-reading frame, before in vivo processing (SEQ ID NO: 17) that are contacted by both, VHH-DS-Cav1-4 and VHH-DS-Cav1-L66, are shown underlined. (D) Co-crystal structure of both ISVDs with RSV prefusion F protein shows high structural conservation of the ISVDs and binding to the same epitope.

Figure 12: Binding specifics of VHH-DS-Cav1-4. (A) CDR3 loop of VHH-DS-Cav1-4 binds to a pocket formed by two protomers of RSV F. (B) CDR2 loop of VHH-DS-Cav1-4 interacts with site II and is joined to CDR3 through a disulfide bond. P1 = protomer 1; P2 = protomer 2.

Figure 13: Binding specifics of VHH-DS-Cav1-L66. (A) CDR3 loop of VHH-DS-Cav1-L66 binds to a pocket formed by two protomers of RSV F. (B) CDR2 loop of VHH-DS-Cav1-L66 interacts with site II and is joined to CDR3 through a disulfide bond. P1 = protomer 1; P2 = protomer 2.

Figure 14. Structure of the F protein in prefusion conformation in complex with motavizumab, AM14, 101F and DS-Cav1-4. Model of the F protein in prefusion conformation in complex with motavizumab, AM14, 101F and DS-Cav1-4. The AM14-Mota-prefusion F structure (4ZYP) and the peptide bound 101F Fab structure (3O41) were aligned to F of the DS-Cav1-4 bound prefusion F structure. The epitope of DS-Cav1-4, as well as that of DS-Cav1-L66, is located between those of AM14, motavizumab and 101F and partially overlaps with each of these.

Detailed description

Definitions

The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. Where the term "comprising" is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated.

Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Plainsview, New York (1989); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New York

(1999), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.

An "immunoglobulin single variable domain" or "ISVD" is an antibody fragment consisting of a single variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12–18 kDa, ISVDs are much smaller than conventional antibodies (150–160 kDa) which are composed of two heavy and two light protein chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain). Generally, an ISVD will have an amino acid sequence comprising 4 framework regions (FR1 to FR4) and 3 complementarity determining regions (CDR1 to CDR3), preferably according to the following formula: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The term "ISVD", as used herein, includes – but is not limited to – variable domains of camelid heavy chain antibodies (VHHs), also referred to as Nanobodies™, domain antibodies (dAbs), and ISVDs derived from shark (IgNAR domains).

The term "binds specifically to the prefusion form of the F protein of RSV", as used herein, refers to the ability of a RSV binding polypeptide (e.g. an antibody, an ISVD) to measurably bind to the prefusion form of the F protein of RSV and not to the postfusion from of the F protein of RSV.

The "prefusion form of the F protein of RSV" refers to the metastable prefusion conformation of the RSV F protein, that is adopted before virus-cell interaction, as described in McLellan et al., 2013. It is distinct from the highly stable postfusion form or postfusion conformation, which is adopted upon fusion of the viral and cellular membranes.

The "monovalent format" of an antibody as used herein refers to an antibody format that can only recognize one antigenic determinant. It excludes multivalent antibody formats that can recognize more than one antigenic determinant, such as – but not limited to – bivalent, trivalent or tetravalent formats.

The term "neutralization activity" as used herein, refers to the fact that the ISVD can inhibit virus infection as measured in an in vitro virus neutralization assay, such as – but not limited to – a plaque reduction assay. Neutralization, also referred to as inhibition, can mean full neutralization (no virus infection is observable) or may mean partial neutralization. For instance, neutralization can mean 10% neutralization, 20% neutralization, 25% neutralization, 30% neutralization, 40% neutralization or more. Particularly, neutralization will be at least 50%, e.g. 50% neutralization, 60% neutralization, 70% neutralization, 75% neutralization, 80% neutralization, 90% neutralization, 95% neutralization or more. The neutralization activity typically will be evaluated against a suitable control (e.g. treatment with an

irrelevant ISVD), as will be readily chosen by the skilled person. For ISVDs with known concentration, the neutralization activity can be expressed as 50% inhibitory concentration (IC50). The IC50 is the ISVD concentration at which 50% inhibition (or neutralization) is achieved. It is a measure of the inhibitory potential, also referred to as potency, of an ISVD.

A "similar neutralization activity" as used herein, refers to a neutralization activity, expressed as IC50, that typically differs ten-fold or less from the neutralization activity it is compared to. More particularly, it differs five-fold or less, or even two-fold or less.

The term "complementarity determining region" or "CDR" refers to a variable loop within the variable regions of either H (heavy) or L (light) chains of immunoglobulins and contains the amino acid sequences capable of specifically binding to antigenic targets. These CDR regions account for the basic specificity of an antibody or antibody fragment for a particular antigenic determinant structure.

The term "epitope" refers to a specific binding site on an antigen or on an antigenic structure for which a polypeptide, such as an ISVD, has specificity and affinity.

The term "conformational epitope" refers to an epitope with the three-dimensional surface features of an antigen, allowing to fit precisely and bind a polypeptide, such as an ISVD. In contrast, linear epitopes are determined by the amino acid sequence (primary structure) rather than by the 3D shape (tertiary structure) of a protein.

"Therapeutic treatment of a RSV infection", as used herein, means any form of treatment of a RSV infection that is administered to a subject after said subject contracted a RSV infection.

"Prevention of a RSV infection", as used herein, means a prophylactic treatment of a RSV infection that is administered to a subject before said subject contracted a RSV infection. Prophylactic treatment may include the use of the present invention as a vaccine.

A "pharmaceutical composition", as used herein, may be any pharmaceutical composition known to the person skilled in the art, including, but not limited to compositions for systemic, oral and intranasal delivery.

A "RSV binding construct that comprises at least one ISVD", as used herein, refers to any binding construct that binds to RSV and comprises one or more ISVDs.

A "host cell", as used herein, may be any cell that is suitable for production of ISVDs or RSV binding constructs.

According to a first aspect, it is an objective of the invention to provide ISVDs that are directed against and/or bind specifically to the prefusion form of the F protein of RSV. Specific binding to the prefusion form of the F protein of RSV means that the ISVD measurably binds to the prefusion form of the F protein of RSV and not to the postfusion form of the F protein of RSV. Specific binding can be influenced by, for example, the affinity of the ISVD and the concentration of the ISVD. The person of ordinary skill in the art can determine appropriate conditions under which the binding ability of the ISVD described herein can be evaluated, such as titration of the ISVD in a suitable binding assay, such as – but not limited to – an enzyme-linked immunosorbent assay (ELISA), or a binding assay based on surface plasmon resonance (SPR) or biolayer interferometry (BLI). Typically, binding to the prefusion form of the F protein of RSV means that the ISVD binds to the wild type form of the F protein as well as to any mutant form of the F protein, as long as the F protein is in the prefusion conformation. It also includes binding to the F protein of both subtypes (A and B) of RSV. In a particular embodiment, above described ISVD binds to the RSV A F protein consensus sequence as set forth in SEQ ID NO: 18. The consensus sequence set forth in SEQ ID NO: 18 was calculated with methods known to the skilled artisan based on 92 RSV A F protein full length sequences listed in the NCBI protein database. Therefore, above described ISVD binds to any of the 92 representative RSV A F protein sequences included to derive to the consensus sequence of SEQ ID NO: 18. In a particular embodiment, above described ISVD binds to the RSV B F protein consensus sequence as set forth in SEQ ID NO: 19. The consensus sequence set forth in SEQ ID NO: 19 was calculated with methods known to the skilled artisan based on 114 RSV B F protein full length sequences listed in the NCBI protein database. Therefore, above described ISVD binds to any of the 114 representative RSV B F protein sequences included to derive to the consensus sequence of SEQ ID NO: 19. In a particular embodiment, above described ISVD binds to both, RSV A F protein as set forth in SEQ ID NO: 18 and RSV B F protein as set forth in SEQ ID NO: 19. In a particular embodiment, above described ISVDs bind exclusively to the prefusion form of the F protein. According to further particular embodiments, above mentioned ISVDs bind exclusively to the prefusion form of the F protein and do not bind to the postfusion form of the F protein. In a particular embodiment, above described ISVDs bind to the prefusion-stabilized RSV F protein of SEQ ID NO: 16. In a particular embodiment, the ISVD may be fused to further moieties.

According to particular embodiments, above described ISVDs bind to an epitope of the RSV prefusion F protein. In particular, they bind to a conformational epitope of the RSV prefusion F protein. In a particular embodiment, above described ISVDs bind a RSV prefusion F conformational epitope comprising amino acid residues T50, G51, W52, S180, G184, V185, P265, I266, T267, N268, D269, Q270, L305, G307, V308, N345, A346, G347, K421, S425, K427, N428, R429, G430, I431, S451, G453, N454, L456, Y458. In particular they bind a RSV prefusion F conformational epitope comprising amino acid residues T50, G51, W52, S180, G184, V185, P265, I266, T267, N268, D269, Q270, L305, G307, V308, N345, A346, G347,

K421, S425, K427, N428, R429, G430, I431, S451, G453, N454, L456, Y458 of RSV prefusion F as set forth in SEQ ID NO: 17.

According to particular embodiments, the ISVD shows in monovalent format a similar neutralization activity of RSV serotypes A and B. Typically, that means that the ISVD interferes with/inhibits/prevents/reverses or slows the ability of the virus to infect a cell. According to these particular embodiments, the ISVD interferes with/inhibits/prevents/reverses or slows the ability of the virus to infect a cell to a similar extent for both the A and B RSV serotypes.

According to particular embodiments, the ISVD comprises a CDR1 sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, a CDR2 sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4 and a CDR3 sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 6, wherein CDR1, CDR2 and/or CDR3 have a 1-, 2- or 3-amino acid difference with any of said foregoing respective SEQ ID NOs. For the ISVD DS-Cav1-4, the sequences of the CDRs are SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5. For the ISVD DS-Cav1-L66 the sequences of the CDRs are SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6.

According to a further aspect, a RSV binding construct is provided, characterized in that said RSV binding construct comprises at least one ISVD. At least one ISVD means that the RSV binding construct may contain more than one ISVD. Next to the one or more ISVDs, the RSV binding construct may contain other moieties linked to the ISVD. Said further moieties may bind to RSV or not. As a non-limiting example, said RSV binding construct may comprise an ISVD that binds to RSV F protein and may be linked (chemically or otherwise) to one or more groups or moieties that extend the half-life (such as – but not limited to – polyethylene glycol (PEG) or a serum albumin binding VHH), so as to provide a derivative of an ISVD of the invention with increased half-life. Typically, said RSV binding construct binds to the RSV prefusion F protein. In a particular embodiment, above described RSV binding construct binds to SEQ ID NO: 17 and/or SEQ ID NO: 18 and/or SEQ ID NO: 19. Said RSV binding construct may be any construct comprising one or more than one RSV binding ISVD.

According to a further aspect, the ISVDs are not provided as such, but are provided as nucleic acid, i.e. nucleic acid molecules encoding ISVDs against the RSV F protein as herein described, particularly against the prefusion form of the F protein. Also provided are vectors comprising such nucleic acids or nucleic acid molecules. According to yet a further aspect, host cells are provided comprising such nucleic acids or such vectors. Typically, the nucleic acids will have been introduced in the host cell by transfection or transformation, although the way in which the nucleic acid is introduced in the host cell is not limiting the invention.

According to yet further embodiments, host cells are provided containing such nucleic acids. Typically, such host cells will have been transformed or transfected with the nucleic acids. A particular use that is envisaged for these host cells is the production of the ISVDs. Thus, such use for production is explicitly envisaged herein. That means that host cells transformed or transfected with the nucleic acid molecules encoding ISVDs can be used for production of the ISVDs.

According to a further aspect, the ISVDs provided herein are for use in medicine. That is to say, the ISVDs against RSV F protein are provided for use as a medicament. The same goes for the nucleic acid encoding the ISVDs, or for the vectors containing such nucleic acids, i.e. it is envisaged that nucleic acid molecules or vectors encoding the ISVDs are provided for use as a medicament. Also the RSV binding constructs comprising at least one ISVD that binds to RSV F protein are provided for use as a medicament. According to particular embodiments, the ISVDs (or RSV binding constructs comprising them or pharmaceutical compositions comprising them or nucleic acids encoding them, or vectors comprising such nucleic acids) are provided for use in treatment or prevention of a RSV infection. This is equivalent as saying that methods are provided for treatment or prevention of a RSV infection for a subject in need thereof, comprising administering an ISVD against RSV F protein to said subject. Here also, the ISVD may be provided as protein (as single domain protein, as part of a RSV binding construct or pharmaceutical composition) or may be administered as a nucleic acid molecule encoding an ISVD against RSV F protein, or as a vector comprising such nucleic acid molecule. If the ISVD (or the RSV binding construct) is administered as protein, different routes of administration can be envisaged. As non-limiting examples, the ISVD may be administered systemically, orally or intranasally, such as e.g. through nasal inhalation. In case the ISVD is provided as a nucleic acid or vector, it is particularly envisaged that the ISVD is administered through gene therapy.

According to a further aspect, pharmaceutical compositions are provided comprising at least one ISVD directed to RSV prefusion F protein. Typically, such pharmaceutical compositions comprise at least one ISVD directed to the prefusion form of RSV F protein. Said pharmaceutical compositions may comprise further moieties. Said further moieties may bind to RSV or not. It is envisaged herein that the pharmaceutical compositions are provided for use as a medicament. Particularly, they are provided for use in therapeutic treatment or prevention of RSV infections. This is equivalent as stating that methods are provided for therapeutic treatment or prevention of RSV infections for a subject in need thereof, comprising administering a pharmaceutical composition as described herein to said subject.

According to further embodiments, a method is provided of therapeutic treatment or prevention of a RSV infection, the method comprising administering to a subject in need thereof the ISVD as described above, the RSV binding construct as described above or the pharmaceutical composition as described above. Said method comprises administering to said subject an ISVD against RSV prefusion F protein.

5   Such methods typically will results in improvement or prevention of symptoms of the infection in said subject. Here also, the ISVD may be provided as protein (as single domain protein, as part of a RSV binding construct or pharmaceutical composition) or may be administered as a nucleic acid molecule encoding an ISVD against RSV F protein, or as a vector comprising such nucleic acid molecule, or as a pharmaceutical composition containing such antibody. Also, RSV binding constructs as described herein

10   are envisaged for administration to a subject in need thereof in methods for therapeutic treatment or prevention of RSV infections.

It is to be understood that although particular embodiments, specific configurations as well as materials and/or molecules, have been discussed herein for cells and methods according to the present invention, various changes or modifications in form and detail may be made without departing from the scope and

15   spirit of this invention. The following examples are provided to better illustrate particular embodiments, and they should not be considered limiting the application. The application is limited only by the claims.

Examples

Materials and methods to the examples

Immunization and VHH library generation

20   A llama was injected subcutaneously on days 0, 7, 14, 21, 28 and 35, each time with 167 µg of purified RSV F protein DS-Cav1. DS-Cav1 is a recombinant RSV F protein stabilized in the prefusion conformation (McLellan et al., 2013). The first two injections were performed with poly-IC (375 µg per injection) as adjuvant, while Gerbu LQ # 3000 was used as adjuvant for the last four injections. Before every immunization blood was taken and plasma prepared to evaluate seroconversion. On day 40, 100 ml of

25   anticoagulated blood was collected for the preparation of lymphocytes.

Total RNA from peripheral blood lymphocytes was used as template for first strand cDNA synthesis with oligodT primer. Using this cDNA, the VHH encoding sequences were amplified by PCR, digested with PstI and NotI, and cloned into the PstI and NotI sites of the phagemid vector pHEN4. Electro-competent E. coli TG1 cells were transformed with the recombinant pHEN4 vector resulting in a VHH library of about

30   5×10^8 independent transformants. 87% of the transformants harbored the vector with the right insert size, as evidenced by PCR analysis of 95 independent transformants.

500 μl of the library stock was infected with VCS M13 helper phage in order to display the VHH sequences (in fusion with M13 PIII) on the phage surface, which were used for bio-panning.

Cells

Hep-2 cells (ATCC, CCL-23), Vero cells (ATCC, CCL-81) and HEK-293T cells (a gift from Dr M. Hall) were grown in DMEM medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2mM L-glutamine, non-essential amino acids (Invitrogen, Carlsbad, California) and 1 mM sodium pyruvate.

Viruses

RSV A2 (VR-1540, ATCC, Rockville), an A subtype of RSV, and RSV B49, a B subtype of RSV (BE/5649/08 clinical strain, obtained from Prof M. Van Ranst, Tan et al., 2013) were propagated by infecting monolayers of Hep-2 cells, with 0.1 MOI in the presence of growth medium containing 1% FCS. Five days after infection the cells and growth medium were collected, pooled and clarified by centrifugation (450 x g). To concentrate the virus, the clarified supernatant was incubated for four h at 4°C in the presence of 10% polyethylene glycol (PEG6000). After centrifugation (30 minutes at 3000 x g), the pellet was resuspended in Hank's balanced salt solution (HBSS), containing 20% sucrose, aliquoted, snap-frozen in liquid nitrogen and stored at -80°C.

RSV-neutralizing activity assay

The llama plasma was tested for neutralizing activity against RSV A2 and RSV B49 by plaque assay. Vero cells were seeded in a 96-well plate (15000 cells/well). The next day, a dilution series of the plasma samples was prepared in Opti-MEM (Gibco) supplemented with 1% penicillin and 1% streptomycin (1/3 dilution series, starting with a 1/4 dilution). An equal volume of RSV A2 suspension (diluted to 1.4 PFU/μl) or RSV B49 (diluted to 2.8 PFU/μl) was added to the plasma samples and the obtained mixtures were incubated for 30 minutes at 37°C. Subsequently, 50 μl of the mixtures was added to the Vero cells, which had been washed with Opti-MEM, and the cells were incubated at 37°C for three h. Next, 50 μl of 1.2 % avicel in DMEM medium supplemented with 2% heat-inactivated FCS, 2mM L-glutamine, non-essential amino acids and 1 mM sodium pyruvate was added to each well and the infection was allowed to continue at 37°C for three days. The cells were fixed for 30 minutes at room temperature by adding 50 μl of a 2% paraformaldehyde solution to the wells. After fixation, the cells were washed twice with phosphate-buffered saline (PBS), permeabilized with 50 μl PBS with 0.2% Triton X-100 for 10 minutes and blocked with PBS containing 1% BSA. Subsequently, polyclonal goat anti RSV serum (AB1125, Chemicon International) was added (1/2000 in PBS containing 0.5% BSA and 0.001% Triton X-100 (PBS/BSA)). After three washes with PBS/BSA the cells were incubated with horseradish peroxidase-

13

conjugated anti-goat IgG (SC2020, Santa Cruz) for 30 minutes. The wells were subsequently washed four times with PBS/BSA and once with PBS. Finally, the plaques were visualized by applying TrueBlue peroxidase substrate (KPL, Gaithersburg). RSV neutralizing activity in crude Pichia pastoris supernatant and of purified VHHs (see below) was also determined with this assay.

5   *Isolation of DS-Cav1 binding VHHs*

We performed one round of panning to enrich for prefusion F (DS-Cav1) binding phages. One well (well A1) on a microtiter plate (type II, F96 Maxisorp, Nunc) was coated overnight with 20 µg DS-Cav1 in PBS. This well, along with an uncoated, negative control well (well A12) was blocked with SEA BLOCK blocking buffer (Thermo Scientific) for one h. Next, 1012 phages in a volume of 100 µl SEA BLOCK blocking buffer

10   were added to these two wells. After one h, the unbound phage particles were removed and the wells were washed ten times with PBST (PBS + 0.5% Tween20). The retained phages were then eluted by applying an alkaline solution consisting of 100 µl of TEA-solution (14% triethylamine (Sigma) pH 10) to the wells for exactly ten minutes. The dissociated phages were then transferred to a sterile tube with 100 µl 1M TRIS-HCl pH 8.0. Tenfold serial dilutions in PBS were prepared with the eluted phages, and 10

15   µl of this dilution series was used to infect 90 µl of TG1 cells (phage display competent E. coli cells). Infection was allowed for 30 minutes at 37°C, after which the bacteria were plated on LB/agar plates with 100 µg/ml ampicillin and 1% glucose. The enrichment for antigen-specific phages by this panning procedure was assessed by comparing the number of phagemid particles eluted from antigen-coated well with the number of phagemid particles eluted from the negative control well.

20   Ninety ampicillin resistant colonies were randomly selected for further analysis by ELISA for the presence of F-specific VHHs in their periplasm. These colonies were first transferred to a fresh LB agar plate with ampicillin and then used to inoculate 1 ml of Terrific Broth (TB) medium with 100 µg/ml ampicillin in a 24 deep well plate. Inoculated plates were incubated at 37°C while shaking for five h. VHH expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) until a concentration of 1 mM. The

25   plates were subsequently incubated overnight at 37°C while shaking. The next day, bacterial cells were pelleted by centrifugation (12 minutes at 3200 rpm) and the supernatant was removed. The cell pellet was resuspended in 200 µl TES buffer (0.2 M TRIS-HCl pH 8, 0.5 mM EDTA, 0.5 M sucrose) and the plates were shaken at 4°C for 30 minutes. Next, water was added to the resuspended cells to induce an osmotic shock, which leads to the release of the periplasmic proteins that include VHHs. The deep well plates

30   were incubated for one h at 4°C while shaking, centrifuged and the supernatant, containing the periplasmic extract was recovered. Four microtiter plates were coated overnight with 100 ng of protein per well in PBS, two with alternating rows of F in the postfusion conformation (McLellan et al., 2011) and BSA, two others with alternating rows of DS-Cav1 and BSA. The coated microtiter plates were then

washed and blocked with 1% milk powder in PBS. After washing of the microtiter plates, 100 μl of periplasmic extract was added to the wells and followed by incubation for one h at 4°C. The plates were washed and 50 μl of a 1/2000 dilution of anti-HA (MMS-101P Biolegend) monoclonal antibody in PBS was added to the plate for one h at room temperature. After washing, a 1/2000 dilution in PBS of

5   horseradish peroxidase (HRP)-linked anti-mouse IgG (NXA931, GE Healthcare) was added and the plates were incubated during one hour. Next, the plates were washed and 50 μl of TMB substrate (Tetramethylbenzidine, BD OptEIA™) was added to every well. The reaction was stopped by addition of 50 μl of 1M H2SO4 after which the absorbance at 450 nM was measured with an iMark Microplate Absorbance Reader (Bio Rad). All periplasmic fractions for which the OD450 values obtained for DS-Cav1

10   or postfusion F were at least two times higher than the OD450 values obtained for BSA, were selected for further analysis. The corresponding bacteria were grown in 3 ml of LB medium with 1/2000 ampicillin for plasmid isolation using the QIAprep Spin Miniprep kit (Qiagen) The cDNA sequence of the cloned VHH was determined by Sanger sequencing using M13RS primer (5'CAGGAAACAGCTATGACC3').

Cloning of VHH into Pichia pastoris expression vector and transformation of Pichia pastoris

15   The VHH sequences, as well as the VHH sequences that were retained after the panning, were PCR amplified from the respective pHEN4 plasmids using the following forward and reverse primers (5'GGCGGGTATCTCTCGAGAAAAGGCAGGTGCAGCTGCAGGAGTCTGGG3'; 5'CTAACTAGTCTAGTGATGGTGATGGTGGTGGCTGGAGACGGTGACCTGG3'). The resulting PCR products were digested with XhoI and SpeI and ligated into XhoI/SpeI digested pKai61 backbone. The origin of the

20   pKai61 vector is described in Schoonooghe et al., 2009. The VHH sequences are cloned in frame with a slightly modified version of the S. cerevisiae a-mating factor signal sequence. This signal sequence directs the proteins to the yeast secretory system, is further processed in the ER and the golgi and will be fully removed before secretion into the extracellular medium. In contrast to the wild-type prepro signal, this modified version does not contain sequences that code for the GluAla repeats (here the signal peptide

25   is efficiently cleaved by the Kex2 endopeptidase without the need for this repeat). The encoded genes contain a C-terminal 6xHis tag and are under control of the methanol inducible AOX1 promoter. The plasmid contains a Zeocine resistance marker for selection in bacterial as well as in yeast cells. The vectors were linearized in the AOX1 promoter (with PmeI) before transformation to P. pastoris to promote homologous recombination in the endogenous AOX1 locus for stable integration into the

30   genome. The resulting vectors were named pKai-DS-Cav1-4, pKai-DS-Cav1-L66, pKai-VHH-F2 and pKai-VHH-F58 and used to transform Pichia pastoris strain GS115 using the condensed transformation protocol described by Lin-Cereghino et al., 2005.

Purification of VHHs produced by Pichia pastoris

Expression of VHH by transformed Pichia pastoris clones was first analysed in 2ml cultures. On day one individual transformants were used to inoculate 2 ml of YPNG medium (2% pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH6, 0.00004% biotine, 1% glycerol) with 100 μg/ml Zeocin (Life Technologies) and incubated while shaking at 28°C for 24 h. The next day, cells were pelleted

5   by centrifugation (8 minutes at 500 g) and the YPNG medium was replaced by YPNM medium (2% pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH6, 0.00004% biotine, 1% methanol) to induce VHH expression and cultures were incubated at 28°c while shaking for 72 h. Fifty 50 μl of 50% methanol was added to the cultures at 72 h, 80 h and 96 h. One hundred h after transfer to methanol containing medium the yeast cells were pelleted by centrifugation (8 minutes at 500 g) and

10   the supernatant was retained to assess the presence of VHH. Crude medium (25 μl) was loaded on a 15% SDS-PAGE gel, after which presence of protein was analysed by Coomassie Brilliant Blue staining. To select VHHs with RSV neutralizing activity, we determined such activity in the crude YPNM supernatant from individual Pichia pastoris transformants by applying serial dilutions of the supernatant in a plaque assay as described above.

15   Pichia pastoris transformants that yielded high levels of VHH in the medium or with high RSV neutralizing activity were selected for scale up using 100 or 300ml Pichia cultures. Growth and methanol induction conditions, and harvesting of medium were similar as mentioned above for the 2 ml cultures. The cleared medium was subjected to ammonium sulphate precipitation (80% saturation) for four hours at 4°C. The insoluble fraction was pelleted by centrifugation at 20,000 g and solubilized in 10 ml HisTrap binding

20   buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4), centrifuged for 10 minutes at 4°C after which the supernatant was loaded on a 1 ml HisTrap HP column (GE Healthcare), pre-equilibrated with the HisTrap binding buffer. After washing the column with at least 10 column volumes of HisTrap binding buffer (until the absorbance reaches a steady baseline), the bound proteins were eluted with a linear imidazole gradient starting from 20 mM and ending at 500 mM imidazole in HisTrap

25   binding buffer over a total volume of 20 ml. Fractions containing the VHH, as determined by SDS-PAGE analysis were pooled, and concentrated to 2 ml with a Vivaspin column (5kDa cutoff, GE Healthcare). These concentrated fractions were then loaded on a Superdex 75 column (160 ml, 0.8 ml/min) in PBS and peak fractions were pooled and concentrated on a Vivaspin column with a 5kDa cutoff. The protein concentration of the pooled fraction was determined by A280 measurement by NanoDrop 1000 with the

30   percent solution extinction coefficient customized to each VHH. The pooled and concentrated fractions were aliquoted and stored at -80°C before further use.

Calculation of 50% inhibitory concentration (IC50) of purified VHHs

To determine the IC50 of the purified VHHs produced by Pichia pastoris threefold serial dilutions prepared in Opti-Mem of these VHHs were evaluated in an RSV neutralization assay as described above. Monoclonal IgGs D25 and AM22 (Beaumont et al., 2012, Spits et al., 2013), both specifically directed at
5   the prefusion conformation of F, were used as positive controls. NB 1.12, a VHH directed against α-macroglobulin was used as a negative control. IC50 values were calculated manually.

In vitro binding of VHHs to DS-Cav1 and postfusion F

The binding of the purified VHHs to DS-Cav1 and postfusion F was tested in a direct ELISA. Microtiter plates (type II, F96 Maxisorp, Nunc) were coated with 100 µl of a 1 µg/ml DS-Cav1 solution or a 1 µg/ml
10   postfusion F solution in PBS. After washing, the plates were blocked for one h with 200 µl of 4% milk in PBS after which they were washed again with PBS once. A 1/3 dilution series of the VHHs (starting from 30 µg/ml) was then applied to the protein-coated wells. After one hour, the plates were washed and a 1/2000 dilution of anti-Histidine Tag antibody (AD1.1.10 AbD Serotec) in PBS was added for an hour. After washing and addition of HRP-linked anti-mouse IgG during one h (in a 1/2000 dilution), the ELISA
15   was developed in the same way as the PE-ELISA described above. For affinity determination, purified DS-Cav1 with a StrepTag II and a 6X HisTag was captured on an NTA sensor chip to approximately 537 response units (RU) for each cycle using a Biacore X100 (GE). The NTA sensor chip was regenerated between cycles using 0.25M EDTA followed by 0.5 mM NiCl2. A buffer-only sample was injected over the DS-Cav1 and reference flow cells, followed by Nb4 or Nb66 2-fold serially diluted from 5 nM to 39.1 pM
20   in HBS-P+, with a duplication of the 1.25 nM concentration. The data were double-reference subtracted and fit to a 1:1 binding model using Scrubber.

Binding of the VHHs to F expressed on the surface of cells that had been transfected with an RSV F cDNA expression vector was evaluated by flow cytometry. HEK293T cells were seeded at 4,000,000 cells per 150 mm tissue culture plate and transfected with 6.4 µg pCAGGS-Fsyn, which encodes a codon-
25   optimized RSV F cDNA, with the FuGENE HD transfection reagent (Promega). To trace transfected cells, transfections were performed in the presence of 6.4 µg of peGFP-NLS. Control transfections were performed with peGFP-NLS only. Eighteen h after transfection the cells were detached with 15 ml trypsin-EDTA solution (0.05% trypsin, 0.5 mM EDTA (pH 8.0)) washed once in PBS and incubated for 30 minutes in PBS containing 1% BSA (PBS/BSA). Subsequently the cells were incubated with the indicated
30   VHH or with RSV-F specific mouse monoclonal antibody (MAB858-1, Chemicon International) at different concentrations as indicated in Figure 8). One h later the cells were washed once with PBS/BSA and incubated with anti-Histidine Tag antibody diluted 1/3000 in PBS/BSA during one h. Next, the cells were

washed once with PBS/BSA and anti-mouse IgG Alexa 633 was added during 30 minutes. After washing the cells three times with PBS, the cells were analyzed using a FACSCalibur flow cytometer. Single GFP expressing cells were selected based on the peak surface of the sideward scatter signal, the peak surface and peak height of the forward scatter signal and the peak surface of the green fluorescence signal.

5   Finally, of these GFP positive single cells, the Alexa 633 fluorescence intensity signal was measured.

Mice

Specific pathogen-free, female BALB/c mice were obtained from Charles River (Charles River Wiga, Sulzfeld, Germany). The animals were housed in a temperature-controlled environment with 12 h light/dark cycles; food and water were provided ad libitum. The animal facility operates under the

10   Flemish Government License Number LA1400536. All experiments were done under conditions specified by law and authorized by the Institutional Ethical Committee on Experimental Animals (Ethical application EC2015-019).

Administration of VHHs and monoclonal antibodies and RSV challenge of mice

Mice were slightly anesthesized by isoflurane before intranasal administration of VHH, palivizumab or

15   RSV challenge virus. VHH, palivizumab (Synagis, Medimmune) and RSV virus were administered in a total volume of 50 µl formulated in PBS, which was distributed equally over the two nostrils. Each group of five mice received 30 µg of DS-Cav1-4, 30 µg of VHH DS-Cav1-L66, 30 µg of VHH-F2 (as a negative control) or 30 µg of palivizumab (as a positive control) four hours before infection with 1,000,000 PFU of RSV A2. All groups also received 30 µg of the negative control VHH-F2 24h after infection.

20   *Determination of lung viral titers by plaque assay*

Five days after challenge, the mice were sacrificed by cervical dislocation. The mouse lungs were removed aseptically and homogenized by vigorous shaking with a Mixer Mill MM 2000 (Retsch) in the presence of a sterile metal bead in 1 ml HBSS containing 20% sucrose and supplemented with 1% penicillin and 1% streptomycin. Lung homogenates were subsequently cleared by centrifugation (10

25   minutes at 2500 rpm) at 4°C and used in duplicate for virus titration on Vero cells. Monolayers of Vero cells were infected with 50 µl of serial 1:3 dilutions of lung homogenates in a 96-well plate in serum-free Opti-MEM medium (Invitrogen) supplemented with penicillin and streptomycin. The plaque assay was further processed as described above. The plaques in each well were counted and for each dilution the number of PFU per lung (1ml) was calculated as follows: number of plaques present in the dilution x the

30   dilution x 20 (= 1000 µl total supernatant volume / 50 µl of supernatant used to infect the first well of the dilution series). The number of PFU in each lung was than calculated as the average of the duplicates.

Determination of lung viral titer by qRT-PCR

To determine the lung RSV load by qRT-PCR, total RNA from the cleared lung homogenates was prepared by using the High Pure RNA tissue Kit (Roche, Mannheim) according to the manufacturer's instructions. cDNA was prepared by the use of random hexamer primers and the Transcriptor First strand cDNA

5   synthesis kit (Roche, Mannheim). The relative levels of genomic RSV M cDNA were determined by qRT-PCR using primers specific for the RSV A2 M gene (5'TCACGAAGGCTCCACATACA3' and 5'GCAGGGTCATCGTCTTTTTC3') and a nucleotide probe (#150 Universal Probe Library, Roche) labeled with fluorescein (FAM) at the 5'-end and with a dark quencher dye near the 3'- end. The qRT-PCR data were normalized to mRPL13A mRNA levels present in the samples of each mouse.

10   *Antibody cross-competition on DS-Cav1-binding*

DS-Cav1 protein (10 µg/ml) was immobilized on AR2G biosensors through amine coupling reaction in acetate buffer (pH 5.0). The reaction was quenched by 1M ethanolamine and DS-Cav1-immobilized biosensors were then equilibrated with assay buffer (PBS with 1% BSA). The biosensors were dipped in competitor antibodies (35 µg/ml in assay buffer) followed by analyte antibodies (35 µg/ml in assay

15   buffer) with a short baseline step in between two antibody steps.

Example 1: RSV neutralizing activity in llama plasma

To assess the induction of humoral anti-RSV responses in the llama after immunization with DS-Cav1, plasma samples obtained before and after each immunization were tested in a RSV-neutralization assay. The samples were tested for their neutralizing activity against RSV-A2 and a clinical strain of RSV B, RSV

20   B49. Figure 1 illustrates that all plasma samples obtained after the fourth immunization have high neutralizing activity against RSV A2 and RSV B49.

Example 2: Isolation of DS-Cav1-specific VHHs

The VHH phage library was subjected to one round of panning on the DS-Cav1 protein. The enrichment for DS-Cav1-specific phages was assessed by comparing the number of phages eluted from DS-Cav1-

25   coated wells with the number of phages eluted from the uncoated wells. The number of eluted phages was estimated indirectly by determining the ampicillin resistance transducing units, i.e. the number of TG1 colonies that had been transduced with the phages eluted in the panning step. This experiment suggested that the phage population was enriched about 140-fold for DS-Cav1-specific phages. Ninety colonies were randomly selected and analyzed by ELISA for the presence of VHHs specific for the

30   prefusion conformation of F (DS-Cav1) versus the postfusion conformation of F in their periplasmic extracts. The result of this ELISA is depicted in Figure 2. Out of the 90 colonies, 37 colonies scored positive

(10 scored positive for binding to both pre- and postfusion F, 19 scored positive for binding to only prefusion F and 8 scored positive for binding to only postfusion F). The VHH sequence of all colonies that suggested binding to pre- and or postfusion F was determined. Twenty eight clones out of 37 had a unique VHH sequence and were selected for further use. The VHH sequences of these clones were cloned into a Pichia pastoris expression vector and the resulting plasmids were subsequently used to transform Pichia pastoris.

Example 3: Testing neutralizing activity in Pichia pastoris supernatants

We also attempted to clone the VHH cDNA library obtained after one round of panning on DS-Cav1 into the Pichia pastoris expression vector pKai61. We used this strategy in order to try to select biologically relevant VHH candidates based on RSV neutralizing activity in the supernatant of individual Pichia pastoris transformants. From the 20 individual Pichia pastoris transformants selected based on binding to F, five had neutralizing activity against RSV A2 (with DS-Cav1-4 being the most potent one), while from 18 clones obtained from the library cloning into pKai61, only one (VHH DS-Cav1-L66) displayed neutralizing activity (Figure 3).

The cDNA sequence of DS-Cav1-4 and DS-Cav1-L66 was determined by Sanger sequencing and the nucleotide sequence as well as the deduced amino acid sequence are shown in Figure 5.

Example 4: Production and determination of IC50 of purified VHHs

Prior to purification, VHH DS-Cav1-4 and VHH DS-Cav1-L66 had the most potent RSV neutralizing VHHs and these two VHHs as well as negative control VHHs F2 and F58 were produced in 300 ml Pichia pastoris cultures and purified by HisTrap purification followed by superdex 75 size exclusion chromatography (Figure 4). VHH F2 and VHH F58 are irrelevant control VHHs obtained from a VHH library derived from a different llama that had been immunized with inactived Junin virus. VHH DS-Cav1-4 and VHH DS-Cav1-L66 in vitro neutralized RSV A2 with an IC50 of 0.021 nM and 0.032 nM, respectively. For neutralization of RSV B49 VHH DS-Cav1-4 and VHH DS-Cav1-L66 displayed an IC50 of 0.015 nM and 0.032 nM, respectively. To evaluate if VHH DS-Cav1-4 and VHH DS-Cav1-L66 could neutralize human Metapneumovirus A and/or B serotypes, pre-determined amounts of GFP-expressing hMPV recombinant viruses (NL/1/00 A1 sublineage or NL/1/99 B1 sublineage, a kind gift of Bernadette van den Hoogen and Ron Fouchier, Rotterdam, the Netherlands) or GFP-hRSV (A2 strain, a kind gift of Mark Peeples, Columbus, Ohio, USA) (MOI 0.3 ffu/cell) were mixed with serial dilutions of VHHs or mAbs and added to cultures of either Vero-118 (hMPV) or HEp-2 cells, growing in 96-well plates. Thirty-six hours later, the medium was removed, PBS was added and the fluorescent intensity of GFP per well was

measured with a Tecan microplate reader M200. Fluorescence values were plotted as percent of a virus control without antibody and used to calculate the corresponding IC50 values.

Example 5: DS-Cav1-4 and DS-Cav1-L66 bind to RSV F in the prefusion state but not to RSV F in the postfusion state.

5   To evaluate the binding ability of DS-Cav1-4 and DS-Cav1-L66 to pre- and postfusion F, we performed an ELISA in which F in either conformation was coated directly on the microtiter plate and a threefold dilution series of VHHs was added to this plate (Figure 7A). We found that VHH DS-Cav1-4 and VHH DS-Cav1-L66 bound specifically to coated prefusion F and not to coated F in the postfusion conformation. To further characterize the binding affinity to prefusion F protein, we performed SPR-based binding

10   experiments. We found that both ISVDs bind to prefusion RSV F with a picomolar affinity. It is surprising that the ISVDs display such a high affinity for its target, as they are monovalent, contrary to conventional monoclonal antibodies such as palivizumab or AM14 (Gilman et al., 2015) that are bivalent by nature. In particular, the off-rate of DS-Cav1-4 is very low.

      Binding of VHH DS-Cav1-4 and VHH DS-Cav1-L66 to F expressed by mammalian cells was also evaluated.
15   HEK293T cells were co-transfected with pCAGGS-Fsyn, encoding a codon optimized F cDNA and peGFP-NLS. Cells were harvested 18 h after transfection and stained with VHH DS-Cav1-4, VHH DS-Cav1-L66, negative control VHHs F58 and F2 and a monoclonal mouse IgG antibody specific for RSV-F. Binding of the VHHs to the GFP positive cells in the co-transfection setting was compared with binding to GFP positive cells that had been transfected with the GFP expression vector only. Clear binding was observed

20   for all dilutions of VHH DS-Cav1-4 and VHH DS-Cav1-L66 and for the three highest concentrations of the positive control monoclonal antibody directed against RSV F (Figure 8).

Example 6: DS-Cav1-4 and DS-Cav1-L66 bind to a new epitope of RSV F

      To investigate whether DS-Cav1-4 and DS-Cav1-L66 bind to the recently described prefusion F specific epitope Ø, we investigated if these VHHs can compete with the epitope Ø specific D25 antibody for the
25   binding to the RSV prefusion F protein by biolayer interferometry (Figure 9). The competition assay illustrates that neither VHH competes with D25. In contrast, both VHHs did compete with each other. These results indicate that both VHHs bind to overlapping epitopes, but those epitopes are different from the D25 epitope Ø.

      Further characterization of the ISVD epitopes confirmed that DS-Cav1-4 and DS-Cav1-L66 bind the same
30   epitope on RSV F, with high structural conservation (Figure 11A-D). In Figure 11C the residues of prefusion-stabilized RSV F protein (full open reading frame, before in vivo processing, SEQ ID NO: 17)

that are contacted by both, DS-Cav1-4 and DS-Cav1-L66 are underlined. In particular, the following amino acid residues of the RSV F protein form part of the epitope of DS-Cav1-4 and DS-Cav1-L66: T50, G51, W52, S180, G184, V185, P265, I266, T267, N268, D269, Q270, L305, G307, V308, N345, A346, G347, K421, S425, K427, N428, R429, G430, I431, S451, G453, N454, L456, Y458. These residues represent the epitope of both DS-Cav1-4 and DS-Cav1-L66. Further details of the binding of the CDR2 and CDR3 loops are shown in Figure 12 (for DS-Cav1-4) and Figure 13 (for DS-Cav1-L66).

The structure of the F protein in prefusion conformation in complex with motavizumab, AM14, 101F and DS-Cav1-4 revealed a new binding epitope (Figure 14). All other antibodies for which the co-crystal structure with RSV F is known bind to an epitope that is different from that bound by DS-Cav1-4 and DS-Cav1-L66. Even the antibodies that compete for binding to prefusion-stabilized RSV F with DS-Cav1-4 (i.e. AM14 and palivizumab) and DS-Cav1-L66 (i.e. AM14, palivizumab and 101F) and for which the binding epitope has been unequivocally determined by co-crystal structure analysis, bind to a different epitope in RSV F. This is shown in Figure 14. We note that palivizumab and motavizumab bind the same epitope in RSV F and that this epitope is present in the prefusion and postfusion state of RSV F.

Example 7: Testing prophylactic anti-RSV activity of VHHs in vivo

To test if prophylactic administration of VHH DS-Cav1-4 or DS-Cav1-L66 can protect against RSV challenge in vivo, female BALB/c mice (five mice per group) received 30 μg of VHH DS-Cav1-4, VHH DS-Cav1-L66, F2 VHH or palivizumab intranasally four h before infection with 1.106 PFU of RSV A2). Twenty four h after challenge, all mice received 30 μg of F2 VHH intranasally. Five days after challenge, the mice were sacrificed and lungs were homogenized in 1 ml of HBSS supplemented with 20% sucrose, penicillin and streptomycin. Mice that had been treated with DS-Cav1-4, DS-Cav1-L66 or palivizumab had no detectable replicating virus in their lungs (except one mouse treated with palivizumab) (Figure 10 A) in contrast to the group which had been treated with the F2 VHH which displayed high levels of replicating virus in their lungs (about 1x105 PFU). As plaque assays used to quantify the level of replicating virus in the lungs can be affected by the presence of neutralizing antibodies or VHHs, we additionally quantified the level of RSV RNA in the lung homogenates by qRT-PCR. Mice that had been treated with DS-Cav1-4 and DS-Cav1-L66 displayed on average more than 3000 times less viral RNA as compared to the F2 treated control mice. Mice that had been treated with palivizumab displayed on average about 100 fold less viral RNA as compared to the F2 treated control mice.

References

1. Gilman, M.S.A., et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. *PLoS Pathog*, **11**, 1-17 (2015).

2. Hultberg, A., et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. *PLoS One*, **6**, e17665 (2011).

3. Lin-Cereghino, J., et al. Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris. *Biotechniques*, **38**, 44, 46, 48 (2005).

4. McLellan, J.S., et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. *J Virol*, **85**, 7788-96 (2011).

5. McLellan, J.S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. *Science* **340**, 1113-1117 (2013).

6. McLellan, J.S., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science* **342**, 592-598 (2013).

7. Scheppens, B., et al. Nanobodies specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. *J. Infect Dis.*, **11**, 1692-701(2011).

8. Schoonooghe, S., et al. Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris. *BMC Biotechnol.*, **9**, 70 (2009).

9. Tan, L., et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. *J Virol.* **87**, 8213-26 (2013).

Claims

1. An immunoglobulin single variable domain (ISVD) that binds specifically to the prefusion form of the fusion (F) protein of respiratory syncytial virus (RSV), characterized in that said ISVD shows in monovalent format a similar neutralization activity of RSV serotypes A and B.

2. The ISVD according to claim 1, characterized in that said ISVD comprises a CDR1 sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, a CDR2 sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4 and a CDR3 sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 6 and wherein CDR1, CDR2 and/or CDR3 have a 1-, 2- or 3-amino acid difference with any of said foregoing respective SEQ ID NOs.

3. A RSV binding construct, characterized in that said RSV binding construct comprises at least one ISVD according to claim 1 or 2.

4. A nucleic acid, characterized in that said nucleic acid encodes at least one ISVD according to claim 1 or 2.

5. A host cell, characterized in that said host cell is transformed or transfected with the nucleic acid according to claim 4.

6. The use of the host cell according to claim 5, for the production of said ISVD.

7. The ISVD according to claim 1 or 2 or the RSV binding construct according to claim 3, for use as a medicament.

8. The ISVD according to claim 1 or 2 or the RSV binding construct according to claim 3, for use in therapeutic treatment or prevention of a RSV infection.

9. A pharmaceutical composition, characterized in that said pharmaceutical composition comprises at least one ISVD according to claim 1 or 2.

10. The pharmaceutical composition according to claim 9, for use as a medicament.

11. The pharmaceutical composition according to claim 9, for use in therapeutic treatment or prevention of a RSV infection.

Figure 1

A

B

Figure 2

Figure 3

A

Figure 3 continued

B

Figure 4

A

Figure 4 continued

B

C

D

Figure 5

A

DS-Cav1-4

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGT

GCAGCCTCTGGATTCACTTTGGATTATTATTACATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCG

CGAGGCAGTCTCATGTATTAGTGGTAGTAGTGGTAGCACATACTATCCAGACTCCGTGAAGGGCCGAT

TCACCATCTCCAGAGACAATGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGAC

ACGGCCGTTTATTACTGTGCGACAATTCGTAGTAGTAGCTGGGGGGGGTTGCGTGCACTACGGCATGG

ACTACTGGGGCAAAGGGACCCAGGTCACCGTCTCCAGCCACCACCATCACCATCACTAG

B

DS-Cav1-L66

CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGT

GCAGCCTCTGGATTCACTTTGGATTATTATTACATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCG

CGAGGGGGTCTCATGTATTAGTAGTAGTCATGGTAGCACATACTATGCAGACTCCGTGAAGGGCCGAT

TCACCATCTCCAGAGACAATGCCAAGAACACGGTGTATCTGCAGATGAACAGCCTGAAACCTGAGGAC

ACGGCCGTTTATTACTGTGCGACAGTAGCTGTAGCACATTTCCGGGGTTGCGGAGTCGACGGCATGG

ACTACTGGGGCAAAGGGACCCAGGTCACCGTCTCCAGCCACCACCATCACCATCACTAG

C

Figure 6

A

RSV A2 neutralisation

- DS-Cav1-4
- DS-Cav1-L66
- nb 1.14
- D25
- AM22

B

RSV B49 neutralisation

- DS-Cav1-4
- DS-Cav1-L66
- nb 1.14
- D25
- AM22

Figure 6 continued

C

	RSV A2 IC$_{50}$		RSV B49 IC$_{50}$	
	ng/ml	nM	ng/ml	nM
DS-Cav1-4	0,31	0,021	0,23	0,015
DS-Cav1-L66	0,46	0,032	0,46	0,032
D25	18,5	0,123	8,24	0,055
AM22	12,35	0,082	74,08	0,494

D

IC$_{50}$ (ng/ml)	hMPV-A1-GFP	hMPV-B1-GFP	hRSV-A2-GFP
F-VHH-4	>30,000	>30,000	0.47
F-VHH-L66	>30,000	>30,000	0.59
Crtl-VHH	ND*	>30,000	>30,000
MPE8	ND	108	47
101F	216	783	124
MF14**	249	319	ND
Motavizumab	ND	ND	33

*ND, not determined
**MF14 is a monoclonal antibody specific for the hMPV F glycoprotein

Figure 7

A

Figure 7 continued

B

Binding of DS-Cav1-4 to prefusion F

$$K_D < 18\ pM$$
$$k_a = 5.7 \times 10^5\ M^{-1}s^{-1}$$
$$k_d < 1.0 \times 10^{-5}\ s^{-1}$$

Binding of DS-Cav1-L66 to prefusion F

$$K_D = 154\ pM$$
$$k_a = 3.3 \times 10^5\ M^{-1}s^{-1}$$
$$k_d = 5.0 \times 10^{-5}\ s^{-1}$$

Binding of DS-Cav1-4 to postfusion F

Binding of DS-Cav1-L66 to postfusion F

Figure 8

Figure 9

|			Analyte		
		F2	DS-Cav1-L66	DS-Cav1-4	D25
Competitor	F2	NB	17.5	12.8	5.4
	DS-Cav1-L66	NB	82.1	58.3	11.7
	DS-Cav1-4	NB	105.0	81.7	18.3
	D25	NB	27.1	8.3	88.4

Figure 10

A

B

Figure 11

A

Rfree/Rwork: 27.7/19.4%

Buried Surface Area
On F_2 Protomer 1: 116 Å^2
On F_1 Protomer 1: 640 Å^2
On F_1 Protomer 2: 400 Å^2
Total: 1156 Å^2

<div align="center">Residues on RSV F contacted by nanobody</div>

QNITEEFYQSTCSAVSKGYLSALR**TGWY**TSVITIELSNIKENKCNGTDAKVK
LIKQELDKYKNAVTELQLLMQSTPATNNRARR

FLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSN**GVS**VL
TFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVN
AGVTTPVSTYMLTNSELLSLINDM**PITNDQK**KLMSNNVQIVRQQSYSIMCII
KEEVLAYVVQLP**LYGV**IDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCD
NAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIM
TSKTDVSSSVITSLGAIVSCYGKT**KCTASNKNRGI**IKTFSNGCDYVSNKGVD
TV**SVGNTLYY**VNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKIN
QSLAFIRKSDELL

B

Rfree/Rwork: 30.21/27.06%

Buried Surface Area
On F_2 Protomer 1: 116 Å^2
On F_1 Protomer 1: 610 Å^2
On F_1 Protomer 2: 450 Å^2
Total: 1176 Å^2

<div align="center">Residues on RSV F contacted by nanobody</div>

QNITEEFYQSTCSAVSKGYLSALR**TGWY**TSVITIELSNIKENKCNGTDAKVK
LIKQELDKYKNAVTELQLLMQSTPATNNRARR

FLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSN**GVS**VL
TFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVN
AGVTTPVSTYMLTNSELLSLINDM**PITNDQ**KKLMSNNVQIVRQQSYSIMCII
KEEVLAYVVQLP**LYGV**IDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCD
NAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIM
TSKTDVSSSVITSLGAIVSCYGKT**KCTASNKNRGI**IKTFSNGCDYVSNKGVD
TV SVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKIN
QSLAFIRKSDELL

Figure 11 continued

C

SEQ ID NO: 17:

```
1   MELLILKANA ITTILTAVTF CFASGQNITE EFYQSTCSAV SKGYLSALRT GWYTSVITIE

61  LSNIKENKCN GTDAKVKLIK QELDKYKNAV TELQLLMQST PATNNRARRE LPRFMNYTLN

121 NAKKTNVTLS KKRKRRFLGF LLGVGSAIAS GVAVCKVLHL EGEVNKIKSA LLSTNKAVVS

181 LSNGVSVLTF KVLDLKNYID KQLLPILNKQ SCSISNIETV IEFQQKNNRL LEITREFSVN

241 AGVTTPVSTY MLTNSELLSL INDMPITNDQ KKLMSNNVQI VRQQSYSIMC IIKEEVLAYV

301 VQLPLYGVID TPCWKLHTSP LCTTNTKEGS NICLTRTDRG WYCDNAGSVS FFPQAETCKV

361 QSNRVFCDTM NSLTLPSEVN LCNVDIFNPK YDCKIMTSKT DVSSSVITSL GAIVSCYGKT

421 KCTASNKNRG IIKTFSNGCD YVSNKGVDTV SVGNTLYYVN KQEGKSLYVK GEPIINFYDP

481 LVFPSDEFDA SISQVNEKIN QSLAFIRKSD ELLSAIGGYI PEAPRDGQAY VRKDGEWVLL

541 STFLGGLVPR GSHHHHHHSA WSHPQFEK
```

D

DS-Cav1-L66
DS-Cav1-4

Figure 12

A

B

Figure 13

A

Figure 13

B

Figure 14

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/00   C07K16/10   A61K39/12   A61P31/14
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K C12N A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2011/064382 A1 (ABLYNX NV [BE]; DEPLA ERIK [BE]; STORTELERS CATELIJNE [BE]) 3 June 2011 (2011-06-03)	1
Y	examples 3-6 -----	1-11
X	WO 2010/139808 A2 (ABLYNX NV [BE]; DEPLA ERIK [BE]; STORTELERS CATELIJNE [BE]; STAELENS S) 9 December 2010 (2010-12-09)	1
Y	examples 9, 12 -----	1-11
	-/--	

[X] Further documents are listed in the continuation of Box C.   [X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 September 2016	06/10/2016

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Lechner, Oskar

Form PCT/ISA/210 (second sheet) (April 2005)

1

C(Continuation).	DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B. SCHEPENS ET AL: "Nanobodies(R) Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 204, no. 11, 12 October 2011 (2011-10-12), pages 1692-1701, XP055218541, CHICAGO, IL. ISSN: 0022-1899, DOI: 10.1093/infdis/jir622	1-11
Y	the whole document	1-11
X	ANNA HULTBERG ET AL: "Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules", PLOS ONE, vol. 6, no. 4, 1 January 2011 (2011-01-01), page e17665, XP055055576, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0017665 abstract; figure 2	1
X,P	GILMAN-MS ET AL.: "Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein", PLOS PATHOG, vol. 11, no. 7, 10 July 2015 (2015-07-10), XP002745533,	1-11
Y,P	the whole document	1-11
X	WO 2009/079796 A1 (ID BIOMEDICAL CORP QUEBEC [CA]; GLAXOSMITHKLINE BIOLOG SA [BE]; BAUDOU) 2 July 2009 (2009-07-02)	1-11
Y	figure 5; examples 1-3, 5, 7, 8	1-11
X	DAVIDE CORTI ET AL: "Cross-neutralization of four paramyxoviruses by a human monoclonal antibody-Supplementary Information", NATURE, vol. 501, no. 7467, 18 August 2013 (2013-08-18), pages 1-16, XP055148969, ISSN: 0028-0836, DOI: 10.1038/nature12442	1-11
Y	the whole document	1-11

-/--

1

INTERNATIONAL SEARCH REPORT

C(Continuation).   DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M. MAGRO ET AL: "Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 8, 21 February 2012 (2012-02-21), pages 3089-3094, XP055067859, ISSN: 0027-8424, DOI: 10.1073/pnas.1115941109 the whole document -----	1-11
Y	J. S. MCLELLAN ET AL: "Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody", SCIENCE, vol. 340, no. 6136, 25 April 2013 (2013-04-25), pages 1113-1117, XP055132644, ISSN: 0036-8075, DOI: 10.1126/science.1234914 abstract -----	1-11
Y	SWANSON KURT A ET AL: "A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes", JOURNAL OF VIROLOGY : A PUBLICATION OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC : ASM, 1967-BALTIMORE, MD : SOC, US, vol. 88, no. 20, 1 October 2014 (2014-10-01), pages 11802-11810, XP008174055, ISSN: 0022-538X, DOI: 10.1128/JVI.01225-14 [retrieved on 2014-07-30] the whole document -----	1-11

1

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 2011064382	A1	03-06-2011	EP	2507262 A1	10-10-2012
			US	2012301469 A1	29-11-2012
			WO	2011064382 A1	03-06-2011
WO 2010139808	A2	09-12-2010	AU	2010255638 A1	12-01-2012
			CA	2764398 A1	09-12-2010
			CN	102459332 A	16-05-2012
			CN	105061592 A	18-11-2015
			EP	2438087 A2	11-04-2012
			JP	2012528584 A	15-11-2012
			KR	20140015113 A	06-02-2014
			NZ	597314 A	26-07-2013
			RU	2011153239 A	20-07-2013
			SG	176095 A1	29-12-2011
			US	2012128669 A1	24-05-2012
			US	2015118233 A1	30-04-2015
			WO	2010139808 A2	09-12-2010
			ZA	201108892 B	29-05-2013
WO 2009079796	A1	02-07-2009	AU	2008340949 A1	02-07-2009
			BR	PI0821532 A2	16-06-2015
			CA	2710600 A1	02-07-2009
			CN	101952321 A	19-01-2011
			EA	201070794 A1	28-02-2011
			EP	2222710 A1	01-09-2010
			JP	5711972 B2	07-05-2015
			JP	2011507533 A	10-03-2011
			KR	20100109933 A	11-10-2010
			SG	188813 A1	30-04-2013
			US	2010291147 A1	18-11-2010
			WO	2009079796 A1	02-07-2009